Irene Ghobrial

Page semi-protected
From Wikipedia, the free encyclopedia

Irene Ghobrial
Born
Egypt
Alma materWayne State University
Cairo University
Scientific career
FieldsScience
Medicine
Oncology
Myeloma
MGUS[1]
InstitutionsMayo Clinic
Dana–Farber Cancer Institute
Harvard Medical School
Websitewww.dfhcc.harvard.edu/insider/member-detail/member/irene-m-ghobrial-md/ Edit this at Wikidata

Irene Ghobrial is an American-Egyptian physician who is a professor at the Dana–Farber Cancer Institute[2] and Harvard Medical School,[1][3] where her research investigates the progression of multiple myeloma. She is interested in why certain patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma develop B cell malignancies. She leads the Stand Up To Cancer multiple myeloma dream team.

Early life and education

Ghobrial was born in Egypt and studied medicine at Cairo University.[4] After graduating, she moved to Detroit, where she completed her specialist training at Wayne State University.[5][6] She has said that she experienced considerable challenges as an immigrant,[citation needed] but ultimately completed her internal training. In 2000, she moved to the Mayo Clinic, where she worked with Karen Hedin and Robert A. Kyle in hematology and oncology.[5]

Research and career

Ghobrial is an expert in multiple myeloma, cancer of the plasma cells. Myleoma is a rare condition that disproportionately impacts African Americans, often at a young age. Ghobrial studies how multiple myeloma use cell dissemination and cell metastasis, and looks to identify warning signs that will permit earlier treatment.[5][7] She believes that these treatments may begin as early as during smouldering myeloma,[8] a precancerous condition that occurs when the immune system is strong and the tumor burden is low.[9]

In 2011, Ghobrial was elected to the American Society for Clinical Investigation.[10] In 2018, she was awarded $10 million from Stand Up to Cancer to establish the Multiple Myeloma Dream Team, which looks to understand the precursors that indicate a risk of developing myeloma.[11] She leads the clinical trial PROMISE (Predicting Progression of Developing Myeloma in a High-Risk Screen Population), which built a cohort to identify individuals with a high likelihood of developing multiple myeloma.[12][13] Her research uses mass spectrometry to screen for monoclonal gammopathies (abnormal proteins found in the blood), and revealed that 13% of her patient cohort had MGUS.[14] Her research demonstrated that Black individuals were considerably more likely to have MGUS than previously expected.[14]

Ghobrial worked with chemists at Massachusetts Institute of Technology to design nanoparticle-based strategies for targeted cancer therapies, which promotes the accumulation of drugs at tumor sites and reduces toxic side effects.[15][16]

In 2022, Ghobrial was awarded the William Dameshek Prize.[17]

In January 2024, The Harvard Crimson reported that Ghobrial, as well as three scientists at the Dana Faber Cancer Institute, have been accused of research misconduct and data falsification.[18]

References

  1. ^ a b Irene Ghobrial publications indexed by Google Scholar Edit this at Wikidata
  2. ^ www.dfhcc.harvard.edu/insider/member-detail/member/irene-m-ghobrial-md/ Edit this at Wikidata
  3. ^ Irene Ghobrial publications from Europe PubMed Central
  4. ^ Gatta, Frances (2023). "How my training helps me to address health disparities in multiple myeloma: Irene Ghobrial's research on early detection of this type of bone-marrow cancer aims to improve patient outcomes, especially among African Americans". Nature. doi:10.1038/d41586-023-01587-9. PMID 37165230.
  5. ^ a b c "Irene Ghobrial, MD". aacr.org. American Association for Cancer Research. Retrieved 2023-05-15.
  6. ^ "Director, Clinical Investigator Research Program – Dana-Farber". physicianresources.dana-farber.org. Retrieved 2023-05-15.
  7. ^ Manier, Salomon; Salem, Karma Z.; Liu, David; Ghobrial, Irene M. (2016). "Future Directions in the Evaluation and Treatment of Precursor Plasma Cell Disorders". American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 35: e400–406. doi:10.1200/EDBK_159010. ISSN 1548-8756. PMID 27249747.
  8. ^ Figueiredo, PhD, Marta. "MMRF Joins Dana-Farber to Advance Research in Smoldering Myeloma". myelomaresearchnews.com. Retrieved 2023-05-15.
  9. ^ "Dr. Ghobrial on Future Efforts to Prevent the Development of Multiple Myeloma". onclive.com. Retrieved 2023-05-15.
  10. ^ "The American Society for Clinical Investigation". the-asci.org. Retrieved 2023-05-15.
  11. ^ Chen, Angus (2022-04-21). "Multiple myeloma is usually detected late. Some researchers think a precursor could help catch it early". statnews.com. Retrieved 2023-05-15.
  12. ^ Ghobrial, MD, Irene (2022-03-22). "Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)". clinicaltrials.gov. Dana-Farber Cancer Institute, Stand Up To Cancer.
  13. ^ "Smoldering Multiple Myeloma – A Unique New Approach – Dana-Farber". physicianresources.dana-farber.org. Retrieved 2023-05-15.
  14. ^ a b El-Khoury, Habib; Lee, David J; Alberge, Jean-Baptiste; Redd, Robert; Cea-Curry, Christian J; Perry, Jacqueline; Barr, Hadley; Murphy, Ciara; Sakrikar, Dhananjay; Barnidge, David; Bustoros, Mark; Leblebjian, Houry; Cowan, Anna; Davis, Maya I; Amstutz, Julia (2022). "Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study". The Lancet Haematology. 9 (5): e340–e349. doi:10.1016/S2352-3026(22)00069-2. ISSN 2352-3026. PMC 9067621. PMID 35344689.
  15. ^ Massachusetts Institute of Technology. "Using bottlebrush-shaped nanoparticles, researchers can identify and deliver synergistic combinations of cancer drugs". phys.org. Retrieved 2023-05-15.
  16. ^ Detappe, Alexandre; Nguyen, Hung V.-T.; Jiang, Yivan; Agius, Michael P.; Wang, Wencong; Mathieu, Clelia; Su, Nang K.; Kristufek, Samantha L.; Lundberg, David J.; Bhagchandani, Sachin; Ghobrial, Irene M.; Ghoroghchian, P. Peter; Johnson, Jeremiah A. (2023). "Molecular bottlebrush prodrugs as mono- and triplex combination therapies for multiple myeloma". Nature Nanotechnology. 18 (2): 184–192. doi:10.1038/s41565-022-01310-1. ISSN 1748-3395. PMC 10032145. PMID 36702954.
  17. ^ "Dana-Farber professor receives William Dameshek Prize for multiple myeloma research". healio.com. Retrieved 2023-05-15.
  18. ^ Paulas, Veronica H.; Ravi, Akshaya (January 12, 2024). "Dana-Farber Cancer Institute Researchers Accused of Manipulating Data".
Retrieved from "https://en.wikipedia.org/w/index.php?title=Irene_Ghobrial&oldid=1220638326"